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2Abstract16
Biotechnology has transformed the potential for plants to be a manufacturing source17
of pharmaceutical compounds. Now, with transgenic and transient expression18
techniques, virtually any biologic, including vaccines and therapeutics, could be19
manufactured in plants. But uncertainty over the regulatory path for such new20
pharmaceuticals has been a deterrent. Consideration has been given to using21
alternative regulatory paths, including those for nutraceuticals or cosmetic agents.22
This review will consider these possibilities, and discuss the difficulties in23
establishing regulatory guidelines for new pharmaceutical manufacturing24
technologies.25
3Plants have always been a rich source of compounds to maintain or improve human26
health [1]. Historically these have been compounds that occur naturally in plants, but27
with the introduction of new plant biotechnology at the end of the last century, the28
possibility emerged to engineer plants to manufacture new compounds, including29
small molecules and biologics, that originate from non-plant sources [2]. Very rapidly,30
the technology to genetically modify almost any plant species was developed,31
including all of the world’s major food and feed crops, and with that arrived the32
prospect of delivering recombinant compounds of potential medical benefit, by the33
oral route [3].34
This boom in plant biotechnology occurred at the same time as the explosion in35
university enterprise activities. A number of new companies including spin-outs were36
established to take advantage of growing interest in the field of “molecular pharming”37
[4]. Although most of these ventures were clearly developing pharmaceutical drug38
targets, for some the regulatory path was not so clear and alternative routes for39
commercial development became of interest. For example, it was considered that40
some products could be developed as nutraceuticals (or food supplements),41
cosmetic ingredients or medical devices, the regulatory path for which are different42
(and less onerous) than for medicines.43
In this article, we shall consider the circumstances under which a plant biotechnology44
product might be regarded as a nutraceutical or food supplement. We shall contrast45
this with how new medicines are regulated with specific reference to plant derived46
products and how this was applied to a monoclonal antibody produced in genetically47
modified plants [5]. We also consider the difficulties in establishing a new regulatory48
path for a novel biotechnology.49
Nutraceuticals and related products50
The populist term “nutraceutical” was coined in 1989 [6, 7], but actually has no51
definition in US or European law. Nutraceuticals are sometimes also described as52
dietary supplements, functional foods, natural health products and “foods for special53
health use” and as such, the term tends to blur the distinction between food and54
medicines. Dietary supplements for example, are recognised in the USA as a55
separate regulatory category of food and are neither food nor drug (Dietary56
Supplement, Health and Education Act, 1994). They are defined as “a product (other57
than tobacco) intended to supplement the diet that contains one or more of the58
following dietary ingredients; vitamins, minerals, amino acids, herbs or other59
botanicals; a concentrate, metabolite, constituent, extract or combination of the60
ingredients listed above”. They must also conform to other criteria:61
 be intended for ingestion in pill, capsule, tablet, powder or liquid form;62
 not be represented for use as a conventional food or as sole item of a63
meal/diet; and64
 be labelled as a “dietary supplement”.65
This definition is quite distinct from a drug, which according to the US Food and Drug66
Administration (FDA) is “an article intended to diagnose, cure, mitigate, treat or67
4prevent disease”, although clearly the marketing objectives of dietary supplements68
often crosses into this spectrum.69
In fact, dietary supplements do not fall under the remit of the US FDA, whose remit is70
restricted to foods, additives, drugs and cosmetics. So whereas for new food71
additives and drugs, the manufacturer must conduct safety studies and submit the72
results to FDA for review and pre-market approval, dietary supplements can be73
marketed without satisfying these criteria and need no pre-market testing.74
In Europe, products are either regulated as foods or medicines, and on a European-75
wide basis, allowing each member state to apply its own regulatory framework. In the76
UK for example, the Medicines and Healthcare Products Regulatory Authority has77
indicated that there are no plans to alter legislation to make specific provision for78
nutraceuticals79
(www.gov.uk/government/uploads/system/uploads/attachment_data/file/358665/App80
endix6.pdf).81
In Europe, a food is defined as “any substance or product whether processed,82
partially processed or unprocessed intended to be, or reasonably expected to be,83
ingested by humans” (Regulation (EC) No. 178/2002). Nutraceutical products can be84
regulated as food, but there can be no implication of medical benefit, ie the85
suggestion that the product can treat or prevent disease. However, beneficial effects86
of nutraceuticals can be made as “health claims” rather than “medical claims”. For87
instance, claims must not state that a nutraceutical will prevent or cure a disease,88
only that it may help to improve health, possibly assisting in the avoidance of the89
onset of illness.90
Pharmaceutical regulation of plant derived drugs91
Pharmaceutical manufacture by plant biotechnology is complicated by the fact that it92
is an emerging technology. As such the regulatory framework was slow to become93
established and still has not been thoroughly tested in any part of the world. Indeed,94
it was not until 2009, that the European Medicines Agency (EMA) published a95
“Guideline on the quality of biological active substances produced by stable96
transgene expression in higher plants” [8]. Previous to that, a “Points to Consider”97
document had been available from 2002, which had been drafted by the agency’s98
Biologics Working Party. This document had not been challenged by any emerging99
product candidate, and was an immature document relating to how Good100
Manufacturing Practice might be applied to plants. The uncertainty relating to101
regulatory requirements for plant biotechnology products, and the prospect of “being102
the first” to engage with the regulatory authority on a new technology was a major103
disincentive for industry to develop this area in Europe.104
105
Edible vaccines106
The prospect of manufacturing medically important recombinant proteins in plants107
rapidly gave rise to the possibility of delivering recombinant vaccines and108
therapeutics in edible plant material as “edible vaccines” [9]. This potentially109
5obscures the lines between pharmaceutical and dietary supplement, and given the110
differences between regulatory oversight of drugs, foods and dietary supplements, it111
is perhaps not surprising that some SMEs become interested in the possibility of112
negotiating an alternative, less complicated and time-consuming regulatory path.113
Although the initial idea of vaccination through consumption of raw plant material (eg114
fruits) has been largely replaced by the concept of oral antigen delivery in processed115
plant material.116
A small number of human clinical trials involving oral delivery of antigen have been117
undertaken. In all cases no major safety concerns were detected, and formulations118
were well tolerated by individuals. The first trials in humans were conducted with the119
LT-B antigen of enterotoxigenic strains of E.coli delivered in transgenic potato [12].120
After consumption of transgenic potato, both serological and mucosal responses121
were detected: 91% of volunteers developed anti LT-B specific serum IgG, and 50%122
also developed anti-LT-B specific secretory IgA antibody (SIgA) in stool samples. In123
a later study in which volunteers were fed the same antigen in maize [13], similar124
results were observed. The authors noted that maize offers substantial benefits125
compared to potato for delivery of edible vaccines, including the availability of raw126
maize preparations, or processed options that require only minimal heat or pressure127
treatments that would not denature antigens.128
Antigen-specific serum antibody responses were also detected in a trial in which129
volunteers were fed lettuce expressing hepatitis B surface [14], When volunteers130
previously vaccinated conventionally against hepatitis B were fed the same antigen131
in potato, antigen-specific serum antibody responses increased up to 56 fold after132
three doses [15].133
Tacket and co-workers expressed the Norwalk virus capsid protein (NVCP) in134
transgenic potatoes and conducted feeding trials in 24 volunteers [16]. Nineteen of135
the individuals developed an immune response of some kind, although the level of136
serum antibody increases were modest, possibly because of pre-existing serum137
antibody to NVCP.138
Finally, human trials have been conducted with rabies glycoprotein and139
nucleoprotein antigen peptides [17]. These antigens were fused to the alfalfa mosaic140
virus (AIMV) coat protein and this chimaera was expressed in spinach using a141
tobacco mosaic virus. Three out of nine volunteers, who had not previously been142
vaccinated, showed detectable levels of rabies virus-neutralising antibodies, when143
fed spinach infected with the recombinant virus.144
Overall, these studies have indicated that an immune response can be mounted in145
individuals fed transgenic plant material expressing a disease antigen. The approach146
so far for edible vaccines has been to adopt the pharmaceutical regulatory route,147
which may not be surprising given the nature of the target products and that they are148
being developed to address important medical needs.149
All of these studies have been performed in the USA, where the regulatory burden150
for early phase clinical trials has been easier to negotiate. In Europe, a Good151
Manufacturing Practice (GMP) compliant manufacturing process has to be in place152
6with a GMP manufacturing licence awarded before any candidate product can be153
tested in human volunteers.154
155
Creating a regulatory path for an emerging biotechnology for pharmaceuticals156
The manufacture of pharmaceuticals is regulated by law, and a code of practice157
termed Good Manufacturing Practice (GMP) represents the minimum standard that a158
medicines manufacturer must meet in their production processes. It was the absence159
of GMP guidelines for medicinal products of plant biotechnology that was a major160
disincentive for commercial development in this area.161
Ultimately, it was an academic consortium, The Pharma-Planta project, funded by162
public research money in the European Union Framework 6 programme, that163
engaged first with the regulators and led to the maturation of the “Points to Consider”164
document into a “Guideline”. As expected, the process was slow and complicated by165
precedent in other regulatory areas. It does however, provide a valuable insight into166
how new regulatory pathways are developed.167
The Pharma-Planta project was an Integrated Project in the area of "Plant platforms168
for immunotherapeutic biomolecule production". The research consortium169
comprised 33 academic and industry partners in Europe and South Africa. The170
specific objectives of the project were to:171
1. Identify the key regulatory issues relating to the GMP-compliant production of172
plant-derived antibodies, following discussions and negotiations with173
European regulatory authorities.174
2. Develop a suitable transgenic plant line producing anti-HIV mAb 2G12 (known175
as P2G12).176
3. Develop procedures for plant cultivation and downstream processing to177
address the key regulatory issues identified above.178
4. Establish specifications for plant-derived mAbs acceptable for human use.179
5. Design and perform a clinical trial to establish the safety of a plant-derived180
mAb.181
The project was originally funded to run from 2004 to 2009, but as the development182
of a new regulatory pathway for plant-derived pharmaceuticals was time consuming,183
it was extended until 2011.184
In the case of monoclonal antibodies (mAbs), the ‘gold standard’ production platform185
is based on mammalian cell cultures that are well established in the industry and186
compliant with GMP. The differences between platforms based on sterile cell187
cultures and non-sterile whole organisms such as plants, was one of the major188
concerns that led to doubts about the potential quality and consistency of mAbs189
produced in plants [18, 19].190
7An HIV neutralising mAb (2G12) was selected, that had previously been expressed191
in CHO cells at GMP, and tested in Phase I clinical trials in human volunteers. This192
provided an important advantage that a target specification had already been agreed193
with regulatory bodies and there was a considerable amount of safety data already194
available for the mAb.195
The production of P2G12 in tobacco for clinical trials required the development of an196
entire production process from first principles, including transformation, the selection197
of lead events, the establishment of working practices for tobacco cultivation that198
satisfied the regulatory bodies in Europe, the definition of Master Seed Banks and199
Working Seed Banks, the development of a unique GMP-compliant downstream200
processing infrastructure and finally the completion of a first-in-human clinical trial to201
test the product for safety [5, 20].202
The application and difficulties of precedent.203
In drawing up a new set of rules (in this case, GMP for medicinal products of plant204
biotechnology) it is always easiest to draw upon precedent from related areas. But205
this brings its own challenges, particularly in trying to accommodate new206
manufacturing within existing guidelines [21, 22].207
Banking systems208
One example of a challenge is the establishment of a banking system for the starting209
point of product manufacture. Systems for banking crop seeds have been well210
established in the agricultural industry for many years [23]. They generally involve a211
“master” seed bank which is used to establish “working banks” that are used for212
distribution to the agricultural industry. The master bank is relatively small, and as it213
diminishes, it can be replenished, thereby ensuring long-term continuity of supply.214
Although similar terminology is used in the pharmaceutical sector the principles215
underlying master and working banks are fundamentally different. A key issue is that216
the master bank may not be replenished, and that sufficient master bank supplies217
need to be established from the start for the lifetime of the product. This ensures218
preservation of the identity of the master bank. Master and working bank systems for219
pharmaceuticals were developed with cell culture systems in mind, rather than whole220
organisms. The logistics of banking vials of cells for periods of up to 20 years differ221
significantly from those for banking plants, or seeds and results in important222
consequences for the choice of banking system for plant production, and possibly for223
the plant species used for manufacture.224
Following regulatory discussion, existing GMP rules were applied and replenishment225
of plant master seed banks for pharmaceutical production was not permitted.226
Transformation events227
The transformation event refers to the specific genetic alteration that occurred in the228
cells used for production. In the case of mammalian cells (eg CHO) for mAb229
production, a detailed characterisation of the transformation event is not usually230
required by the regulators.231
8However, in the case of plants a different approach was taken, due to the existing232
precedent of GM foods. Under GM food legislation in Europe, a precise233
characterisation of the transformation event is necessary, including flanking DNA234
sequences, and single copy insertion events are significantly favoured [24]. This led235
to the requirements for transformation event characterisation in genetically modified236
plants for mAb production being much more onerous than those required from CHO237
manufacture. It was a significant deterrent to the use of plants with multiple238
transgene copies and insertion sites, which in turn restricted the product expression239
yields that were achievable [25].240
Plant cultivation241
A key component of the acceptance of plant manufacturing being GMP compliant242
was the establishment of Standard Operating Procedures (SOPs) describing the243
cultivation of the plants [25].244
“Good agricultural practice” (GAP) had previously been developed for production of245
food for consumers or further processing that is safe and wholesome. Some246
organisations like the World Health Organisation had established GAP guidelines for247
medicinal plants [26]. Early expectations were that this precedent could be applied to248
GM plants for pharmaceutical production. However, it rapidly became clear that the249
established GAP systems were inadequate for this purpose, and a major part of250
Pharma-Planta’s effort was directed towards the establishment of revised SOPs for251
GAP for monoclonal antibody production.252
The three examples outlined above, illustrate some of the difficulties in developing253
new regulatory paths. In some cases, systems that have been well established in254
other areas (eg food crop seed banking; or good agricultural practice) are not255
deemed appropriate for a new manufacturing platform’s compliance. In other cases,256
a precedent that was created for a completely different reasons (eg genetic257
characterisation of the transformation event) is applied, even though the same258
requirements are not applied to other technologies used for the same application.259
Outcome of the Pharma-Planta project260
The most important outcomes from the Pharma-Planta project was the granting of a261
GMP manufacturing license to Fraunhofer IME for plant derived monoclonal262
antibodies by the national German regulatory authority, and the approval of the263
clinical trial application by the national UK regulatory authority [5]. These two264
achievements demonstrated that a GMP compliant process for transgenic plants265
could be developed and was acceptable to pharmaceutical regulators. They266
established a regulatory approach and path in Europe that could be adopted or267
adapted by other parties.268
The Pharma-Planta clinical trial was completed in November 2011. It represented269
the first ever administration of a plant-derived mAb by the vaginal route in humans270
and the first use of a GMP-compliant transgenic plant-derived mAb in humans. No271
major safety issues were identified, the plant-derived antibody was safe and well272
tolerated in healthy women when administered intravaginally in single doses of up to273
28 mg.274
9The first commercial products of Molecular Pharming.275
In parallel with these developments in Europe, the first two products of Molecular276
Pharming have been brought to the market in recent years. The first, Elelyso is an277
enzyme replacement therapy for humans, and the second, Interberry-alpha, also a278
biologic, is targeted at the veterinary market. In both cases, the products were279
developed and licensed as pharmaceuticals by the appropriate regulatory authority.280
Elelyso281
Protalix, an Israeli enterprise established in 1993, had considerable success in282
producing glucocerebrosidase (prGCD / ELELYSO™) in a carrot cell fermentation283
system. Protalix advanced ELELYSO through clinical trials and subsequent new284
drug approval regulation by the FDA, and it remains the only molecular pharming285
product currently licensed for human use. Human glucocerebrosidase is an enzyme286
involved in glycolipid metabolism, and deficiency of this enzyme leads to Gaucher’s287
disease, an incapacitating condition for which the only treatment is continuous288
enzyme replacement therapy. Gaucher’s disease is generally considered an ‘orphan289
disease’, based on the relatively low incidence and distribution of the condition290
worldwide [27].291
Recombinant human glucocerebrosidase had previously been marketed by292
Genzyme (Cerezyme™) and Shire (VpriV®) using a mammalian cell production293
platform. The uptake of human glucocerebrosidase into target cells (primarily294
macrophages) requires the correct processing of four typically occupied295
glycosylation sites [27]. Paucimannosidic glycans are ligands for mannose receptors296
expressed by macrophages, whereas the heterologous complex or high mannose297
glycans formed in mammalian cell cultures do not display correctly linked mannose298
moieties required for binding. In order to expose these residues, downstream299
enzymatic reactions are required, which adds to process cost and complexity. In300
contrast, Protalix took advantage of the well-characterised plant secretory pathway301
by modifying the protein to alter its accumulation pattern within the cells, leading to a302
homogenous population of paucimannosidic glycans.303
In 2009, the US FDA and Genzyme issued a notification to healthcare professionals304
about the potential for foreign particle contamination of several Genzyme products305
including Cerezyme™ (FDA Safety Alert, 2009). This event is believed to have306
triggered awareness of the lack of FDA-approved therapeutic alternatives and307
interest in identifying manufacturing alternatives.308
The subsequent commercial approval for Protalix’s ELELYSO resulted almost309
immediately in the signing of a collaboration agreement with Pfizer for further310
development and commercialization.311
Interberry-alpha312
Interberry-alpha is recombinant canine interferon-alpha produced by the Hokusan313
Co. Ltd in the National Institute of Advanced Industrial Science and Technology314
(AIST), Hokkaido, Japan. Interberry-alpha is manufactured in genetically modified315
strawberries in a hermetically sealed “Type 2” facility specifically designed for316
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transgenic plants and the avoidance of gene release into the environment.317
Manufacturing and marketing approval for the product was granted by the Japanese318
Ministry of Agriculture, Forestry and Fisheries, and processed strawberries were319
marketed from 2014 for the treatment of periodontal disease in dogs.320
Conclusions321
It is perhaps interesting that both ELELYSO and Interberry-alpha were produced in322
edible plant species and could have adopted a food supplement regulatory path.323
Similarly all the edible vaccines tested so far have adopted a more complicated324
pharmaceutical regulatory route. So, despite much discussion and conjecture within325
the field, it seems that most are choosing the conventional regulatory approach,326
presumably to realise the advantages of medical claims, and possibly because327
ultimately, this is considered to be the “right” path to take. It is likely however, that all328
future decisions will be taken case-by-case, and on the basis of commercial329
considerations and regulatory approaches taken at national level.330
The Pharma-Planta consortium project overcame a major roadblock by taking on the331
challenge of being the first organisation in Europe to engage with the regulatory body332
and establish an accepted manufacturing process for transgenic plant derived333
biologics. In so doing, it encountered many obstacles and difficulties which led to334
considerable delay. Fortunately, this delay could be absorbed because of the public335
nature of the project, whereas similar delay could spell disaster for a commercial336
entity. There is thus a line of thought that suggests this type of “ice breaker” activity337
should be a role of academia, given the commercial uncertainties that are ever338
present. It is hoped that now this barrier has been overcome, that the decision to339
adopt a pharmaceutical regulatory approach over other apparently simpler routes to340
commercialisation will have become more straightforward.341
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